TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25591391

Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine plus azithromycin (SPAZ) monthly from second trimester
Number of subjects: 2793

Group type: COMPARATOR
Intervention: Sulphadoxine‐pyrimethamine and chloroquine (SPCQ) given once, followed by SPCQ placebo (control)
Number of subjects: 2793
Study: 23429964

Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol 320 mg bid for 12 weeks
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol 320 mg bid for 12 weeks (subgroup study)
Number of subjects: 343
Study: 21166851

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 119

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 119
Study: 18811806

Group type: EXPERIMENTAL
Intervention: Primary implants for LBBB
Number of subjects: 328

Group type: COMPARATOR
Intervention: Upgrades from RVS
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Total cohort (LBBB and RVS)
Number of subjects: 328
Study: 16523371

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal approach
Number of subjects: 44

Group type: COMPARATOR
Intervention: Open anterior mesh repair
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 12911281

Group type: EXPERIMENTAL
Intervention: New AChR antibody test using a mixture of AChR from TE671‐ε and TE671‐γ cells
Number of subjects: 365

Group type: COMPARATOR
Intervention: Standard assay using fetal type AChR
Number of subjects: 365
Study: 10766581

Group type: EXPERIMENTAL
Intervention: Azithromycin (1200 mg weekly)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 520
Study: 9121823

Group type: EXPERIMENTAL
Intervention: Postoperative pain intensity (RIPP) in chronic pain patients
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Postoperative pain intensity (RIPP) over time
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: State anxiety and depression scores preoperatively
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: State anxiety and depression scores one year after surgery
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Consumption of analgesics (opioids and NSAIDs)
Number of subjects: 93
Study: 1848392

Group type: EXPERIMENTAL
Intervention: Lisinopril (equal milligram dosage)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Enalapril (constant dosage)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg tablet per day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg tablet per day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg tablet per day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 47
Study: 6653136

Group type: EXPERIMENTAL
Intervention: Conventional capsules (600 mg disopyramide in 3 divided doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional capsules (500 mg disopyramide daily for 11 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sustained-release tablets (500 mg disopyramide daily for 11 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sustained-release tablets (500 mg disopyramide daily for 30 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Disopyramide treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Disopyramide sustained-release tablets
Number of subjects: 33
Study: 30785827

Group type: EXPERIMENTAL
Intervention: Defactinib
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344

Group type: COMPARATOR
Intervention: Defactinib and Placebo
Number of subjects: 344
Study: 30517586

Group type: EXPERIMENTAL
Intervention: Guided imagery relaxation therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 24
Study: 26303936

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 23
Study: 24419112

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus hypnosis (CBTH)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 200
Study: 22442025

Group type: EXPERIMENTAL
Intervention: High-frequency IPC (2-s inflation/3-s deflation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-frequency IPC (4-s inflation/16-s deflation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IPC treatment
Number of subjects: 30
Study: 20465893

Group type: EXPERIMENTAL
Intervention: Ozone therapy for one week
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ozone therapy for two weeks
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ozone therapy for four weeks
Number of subjects: 187
Study: 17468821

Group type: EXPERIMENTAL
Intervention: 100 mg bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 mg ropivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 150 mg ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline with epinephrine 1/200,000
Number of subjects: 80
Study: 14699453

Group type: EXPERIMENTAL
Intervention: Miltefosine (2.5 mg/kg per day for 28 days)
Number of subjects: 80
Study: 12048432

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 426

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 426
Study: 9524514

Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage using Solcotrans Plus Orthopaedic devices
Number of subjects: 161
Study: 8792486

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg) twice daily for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets twice daily for 10 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2265168

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% bupivacaine without epinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (0.5% bupivacaine with and without epinephrine)
Number of subjects: 20
Study: 6895644

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: maintenance sucralfate
Number of subjects: 0
Study: 29290547

Group type: EXPERIMENTAL
Intervention: Condition 2 (room without acoustic treatment with noise reproduction)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Condition 1 (room without acoustic treatment and without noise reproduction)
Number of subjects: 27
Study: 29020983

Group type: EXPERIMENTAL
Intervention: AZD5069 (40 mg) administered orally twice daily for 24 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26185325

Group type: EXPERIMENTAL
Intervention: 0.1‐mmol/kg gadobenate
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 0.05‐mmol/kg gadobenate
Number of subjects: 177

Group type: COMPARATOR
Intervention: 0.1‐mmol/kg gadoterate
Number of subjects: 177
Study: 25252423

Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 169

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 169
Study: 22348338

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control gene hARP-P0
Number of subjects: 0
Study: 20651683

Group type: EXPERIMENTAL
Intervention: Anti-diabetic PPARγ 3 ligands (rosiglitazone, MRL24)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study: 16968726

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin-alpha (SC-EPO; EPREX; 1000 U twice weekly)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Subcutaneous epoetin-alpha (SC-EPO; 2000 U three times weekly)
Number of subjects: 197
Study: 16287442

Group type: EXPERIMENTAL
Intervention: 5 mL lidocaine‐prilocaine cream
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5 mL placebo
Number of subjects: 200
Study: 11888953

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg, once daily for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo tablet, once daily for 4 weeks
Number of subjects: 29
Study: 10220627

Group type: EXPERIMENTAL
Intervention: Prophylactic lidocaine
Number of subjects: 43704

Group type: COMPARATOR
Intervention: No lidocaine
Number of subjects: 43704
Study: 7825527

Group type: EXPERIMENTAL
Intervention: 8 g fine coffee grounds per day for 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fine coffee grounds for 10 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coarse coffee grounds for 10 days
Number of subjects: 15
Study: 2083170

Group type: EXPERIMENTAL
Intervention: Garlic powder (Kwai) for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 47
Study: 670607

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 54
Study: 31988276

Group type: EXPERIMENTAL
Intervention: Circulating tumor-derived DNA (ctDNA) analysis through ultrasensitive targeted sequencing of matched cfDNA and white blood cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative treatment and surgical resection (multimodal treatment).
Number of subjects: 0
Study: 31236679

Group type: EXPERIMENTAL
Intervention: Uncomplicated acute appendicitis (surgical treatment arm of the APPAC trial)
Number of subjects: 0
Study: 28464867

Group type: EXPERIMENTAL
Intervention: Behaviour change communication (BCC) on maternal nutrition during pregnancy, exclusive breastfeeding, and complementary feeding, along with prenatal nutritional supplement (PNS) and complementary food supplement (CFS)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: BCC with PNS
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: BCC with CFS
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: BCC alone
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Routine health and nutrition services (comparison arm)
Number of subjects: 1500
Study: 25929208

Group type: EXPERIMENTAL
Intervention: Arabic version of SRS‐22r questionnaire (reliability testing group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Arabic version of SRS‐22r questionnaire (validity testing group)
Number of subjects: 81
Study: 23218022

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus low-dose risperidone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Supportive therapy plus placebo
Number of subjects: 115
Study: 21690083

Group type: EXPERIMENTAL
Intervention: DIR/Floortime™ intervention (average of 15.2 hours/week for three months)
Number of subjects: 0
Study: 19453962

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 12
Study: 16713737

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 14747294

Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 41
Study: 11697643

Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies involving vaccines
Number of subjects: 0
Study: 9549738

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 2 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% 2 mg.kg‐1
Number of subjects: 40
Study: 9115058

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam 4 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam 8 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2716477

Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day) with naloxone (1.6 mg/h for 4 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bromocriptine (5 mg/day) with saline
Number of subjects: 9
Study: 1017879

Group type: EXPERIMENTAL
Intervention: +Pat. (antibiotic prophylaxis with penicillins or cephalosporins)
Number of subjects: 133

Group type: COMPARATOR
Intervention: ‐Pat. (no antibiotic treatment)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Intubated patients
Number of subjects: 133
Study: 31326458

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus fixed-dose combination glimepiride 1 mg and metformin 500 mg twice daily (G/M group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Insulin glargine plus glimepiride 4 mg once daily (G group)
Number of subjects: 97
Study: 26975399

Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% (four times daily for 6 weeks post-surgery)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional postoperative care with steroid drop
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1%
Number of subjects: 108
Study: 26088896

Group type: EXPERIMENTAL
Intervention: Perampanel (DB-PER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (DB-PBO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel (DB-PER 12 mg)
Number of subjects: 0
Study: 23510102

Group type: EXPERIMENTAL
Intervention: Motivational interviewing counseling with 21‐mg nicotine patch
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard care (one session of brief advice to quit smoking) with 21‐mg nicotine patch
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Motivational interviewing counseling
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 430
Study: 21864166

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily for 1 year)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1142
Study: 19825960

Group type: EXPERIMENTAL
Intervention: DNA cytometry testing
Number of subjects: 23993

Group type: COMPARATOR
Intervention: Cytologic testing
Number of subjects: 23993

Group type: EXPERIMENTAL
Intervention: Both tests used together
Number of subjects: 23993

Group type: EXPERIMENTAL
Intervention: Adverse events after treatment
Number of subjects: 23993
Study: 16415935

Group type: EXPERIMENTAL
Intervention: Lofric catheter
Number of subjects: 196

Group type: COMPARATOR
Intervention: SpeediCath catheter
Number of subjects: 196
Study: 15288215

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 11737375

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Saquinavir hard gel
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 823
Study: 9161875

Group type: EXPERIMENTAL
Intervention: GH treatment at 0.1 IU/kg/day
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: GH treatment at 0.2 IU/kg/day
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: GH treatment at 0.3 IU/kg/day
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study: 8260285

Group type: EXPERIMENTAL
Intervention: Remotely controlled mechanical pump for contrast injection
Number of subjects: 319

Group type: COMPARATOR
Intervention: Hand injection of contrast
Number of subjects: 319
Study: 3288942

Group type: EXPERIMENTAL
Intervention: Hypnosis-induced analgesia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Relaxation-induced analgesia
Number of subjects: 28
Study: 31350080

Group type: EXPERIMENTAL
Intervention: a‐tDCS and training
Number of subjects: 38

Group type: COMPARATOR
Intervention: sham a‐tDCS and training
Number of subjects: 38

Group type: COMPARATOR
Intervention: training only
Number of subjects: 38
Study: 28302411

Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 3484

Group type: COMPARATOR
Intervention: IIV3-YAM
Number of subjects: 3484

Group type: COMPARATOR
Intervention: IIV3-VIC
Number of subjects: 3484
Study: 26692555

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 200
Study: 23771530

Group type: EXPERIMENTAL
Intervention: Fatigue-inducing protocol consisting of intermittent isometric contractions of the leg extensors or flexors using a 0.6 duty cycle (6 s contraction, 4 s relaxation) at 60 % of MVC until volitional fatigue
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fatigue-inducing protocol
Number of subjects: 36
Study: 21794012

Group type: EXPERIMENTAL
Intervention: Cellooligosaccharide (CE) feeding group (n = 16)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Synbiotic (SB) feeding group (n = 18)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 52
Study: 18653328

Group type: EXPERIMENTAL
Intervention: Celecoxib (400mg b.i.d. for 7 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 23
Study: 17276955

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade cardioplegia (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent antegrade cardioplegia supplemented by antegrade perfusion of vein grafts (Group 2)
Number of subjects: 20
Study: 12942029

Group type: EXPERIMENTAL
Intervention: Low dose of spironolactone plus standard therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard therapy only (Control group)
Number of subjects: 51
Study: 10780135

Group type: EXPERIMENTAL
Intervention: Strength of husbands' alliance assessed at Session 1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Strength of wives' alliance assessed at Session 1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Alliance
Number of subjects: 70
Study: 8761840

Group type: EXPERIMENTAL
Intervention: Exercise training based on 60% to 80% of peak oxygen intake (VO2max) and/or ventilatory threshold (VT) with perceived exertion of 12 to 14 on the Borg scale
Number of subjects: 20
Study: 1342896

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily for 7 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily for 7 days
Number of subjects: 142
Study: 3908127

Group type: EXPERIMENTAL
Intervention: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group A with heavy osmotic hydration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group B over 3 consecutive days
Number of subjects: 20
Study: 30747780

Group type: EXPERIMENTAL
Intervention: Guided imagery intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 28919191

Group type: EXPERIMENTAL
Intervention: RESTORE program (9‐12 individual yoga sessions)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 68
Study: 26385228

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (100 mg daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25297013

Group type: EXPERIMENTAL
Intervention: ALD403 1000 mg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 23427759

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anesthesia (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Digital-guided anesthesia (group B)
Number of subjects: 150
Study: 19074540

Group type: EXPERIMENTAL
Intervention: Phobic exposure in spider phobic subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study: 18589423

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg daily for 15 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15827459

Group type: EXPERIMENTAL
Intervention: Mother's milk odor
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vanilla smell
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unfamiliar odor
Number of subjects: 44

Group type: COMPARATOR
Intervention: No odor (Control group)
Number of subjects: 44
Study: 11830307

Group type: EXPERIMENTAL
Intervention: Accelerated regimen (AF): 66Gy given in 33 fractions over 38 days.
Number of subjects: 395

Group type: COMPARATOR
Intervention: Conventional regimen (CF): 66Gy given in 33 fractions over 45 days.
Number of subjects: 395
Study: 10512078

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both (Pimozide and Lithium)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 7740123

Group type: EXPERIMENTAL
Intervention: Electrodermal conditioning with intermixed pre-training and compound training trials; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overshadowing control group; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 2167327

Group type: EXPERIMENTAL
Intervention: Dental tape
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Waxed dental floss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Superfloss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All types of dental floss
Number of subjects: 20
Study: 6290754

Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and vincristine (ACO)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Etoposide maintenance therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: No further maintenance therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Irradiation towards primary disease sites
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen (ACO)
Number of subjects: 103
Study: 30897134

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and pulmonary rehabilitation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care cohort
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity or sleep
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour or light physical activity
Number of subjects: 95
Study: 28337854

Group type: EXPERIMENTAL
Intervention: Silk fibroin film
Number of subjects: 71

Group type: COMPARATOR
Intervention: Commercial dressing
Number of subjects: 71